Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent.

It is designed for the treatment of squamous cell carcinoma.

[1] This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.